The latest tempest over a dramatic drug price hike riles two powerful senators — who can't actually do anything about it
First Nostrum CEO Nirmal Mulye caught the attention of FDA commissioner Scott Gottlieb when he jacked up the price of an old antibiotic from $474.75 to $2,392 last month. Now he has a pair of angry US senators on the warpath over his controversial, Martin Shkreli-like comments about the “moral requirement” of earning money for his investors and comparing the move to pricing art.
Coming in from opposite sides of the aisle, Claire McCaskill and Susan Collins let it be known that the original article from the Financial Times that got the show started had incensed them.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.